In the absence of a donor alternative a stem cell transplantation consisting of two cord blood components originating from the haploidentical brother was performed in a 2-year-old girl with c-ALL, early CNS relapse and 7% of blast cells in the BM 14 days before transplantation. Because of various ongoing infectious complications at that time, 1/8 of the immunogenetically acceptable sibling cord blood was ex vivo expanded 10 days before the transplantation date. The total CB consisting of 1.17 ؋ 10 9 NC was cryopreserved in four separate bags. The one containing 1/8 of the total CB with 1.4 ؋ 10 8 NC CliniMACS selected CD34 ؉ cells was expanded in the presence of 100 ng/ml G-CSF, 100 ng/ml TPO and 100 ng/ml flt3-L in 10% autologous CB plasma and X-VIVO 10 medium at day ؊10 before transplantation. This expanded cell population was sterile and consisted of about 60% granulocytic cells (CD13 ؉ Cord blood (CB) has clearly become an alternative and even a promising source of marrow repopulating cells for the treatment of pediatric patients over the past 10 years. Hitherto, over 1000 unrelated and related cord blood transplants have been performed, mostly in pediatric patients. [1] [2] [3] [4] [5] In spite of one or two HLA-antigen mismatches these patients have engrafted with no or only moderate acute or chronic GVHD. [1] [2] [3] [4] [5] Due to the relatively low numbers of cells in the primary residual cord blood including colony-forming units and CD34 ϩ cells, presently there are certain limitations for the widespread use of CB as a source of hematopoietic cells for transplantation, particularly in adults or overweight patients. Delays in engraftment for neutrophils and platelets have been observed when lower cell numbers were transplanted, resulting in more frequent infectious complications after transplantation. With about 40% frequency the latter were the major cause of death in the most recent analysis published.
aplastic phase observed after this simultaneous CB cell component transplantation. The patients T cell and NK cell reconstitution could be detected at day ؉37 with 330 CD3
؉ cells/l and 40 CD56 ؉ cells/l, respectively. The time to reach an absolute platelet count of 20 000 (50 000)/l was 75 (103) days. The disease-free survival now exceeds 1 year in complete remission without chronic GVHD or any other health problems. These data show that the applicability of ex vivo expanded committed progenitors and LTC-IC, even in high risk leukemia at the time of transplantation, is feasible and can provide sufficient myeloid progenitors resulting in rapid engraftment able to clear bacterial pneumonia and sepsis. In addition, accelerated hematopoietic reconstitution apparently served as a well functioning platform for definitive graft-versus-leukemia activity. This transplantation of defined ex vivo generated components presents a feasible and generally applicable approach and may open a promising new avenue for cell therapy in malignant diseases. Keywords: cord blood; clinical ex vivo expansion Cord blood (CB) has clearly become an alternative and even a promising source of marrow repopulating cells for the treatment of pediatric patients over the past 10 years. Hitherto, over 1000 unrelated and related cord blood transplants have been performed, mostly in pediatric patients. [1] [2] [3] [4] [5] In spite of one or two HLA-antigen mismatches these patients have engrafted with no or only moderate acute or chronic GVHD. [1] [2] [3] [4] [5] Due to the relatively low numbers of cells in the primary residual cord blood including colony-forming units and CD34 ϩ cells, presently there are certain limitations for the widespread use of CB as a source of hematopoietic cells for transplantation, particularly in adults or overweight patients. Delays in engraftment for neutrophils and platelets have been observed when lower cell numbers were transplanted, resulting in more frequent infectious complications after transplantation. With about 40% frequency the latter were the major cause of death in the most recent analysis published. 5 Therefore, ex vivo expanded CB infused into the patient at the time of transplantation as the nonexpanded cord blood from the same donor could increase the number of immediately available progenitor cells responsible for short-term engraftment. While expansion with recombinant hematopoietic growth factors has been shown to increase the number of multipotent colony-forming cells, prolonged culture, however, often resulted in an exhaustion of the most primitive progenitors. 6, 7 Therefore, it was attempted to expand only 1/8 of the total CB product 10 days ahead of the scheduled transplant date while maintaining the majority of the CB unmanipulated. This is the first report to demonstrate the general feasibility of the usefulness of simultaneous transplantation of an ex vivo expanded part of a CB unit together with the nonmanipulated CB in contrast to previous clinical studies, where CB was thawed only at the time of transplantation, ex vivo expanded and infused into the patient 10-12 days after transplantation of the unmanipulated CB unit.
Patient
An 8-month-old girl was found to have c-ALL in December 1996 with involvement of both kidneys but without hepatosplenomegaly. She was treated according to the NHL-BFM90 protocol, 8 but suffered an early isolated CNS relapse 12 months after initial diagnosis and received the ALL-BFM-relapse protocol. 9 Due to a relatively rare HLAgenotype (Table 1) neither a related nor an unrelated HLAidentical bone marrow donor could be found in time.
In the absence of a donor this girl was transplanted with the CB of her haploidentical brother born in December 1997, fortunately being a 5/6 HLA antigen match with one mismatch in DRB1. However 2 weeks before transplantation, again 7% of blast cells in the BM of the patient were detected.
The patient conditioning before stem cell transplantation was as follows: total body irradiation TBI 12 Gy (with lung shielding at 8 Gy), thiotepa 2 ϫ 5 mg/kg BW for 2 days, cyclophosphamide 2 ϫ 60 mg/kg BW for 2 days. The unmanipulated CB unit was infused at day 0 and ϩ1 consisting of a total of 4.4 ϫ 10 7 /kg BW after thawing. In addition 1 ϫ 10 7 NC/kg BW ex vivo expanded cells generated from another bag of the same cord blood were infused at day ϩ1. Other characteristics of the cord blood and the recipient are presented in Table 1 . Prophylaxis against GVHD consisted of 3 mg cyclosporine/kg BW per day starting at day Ϫ1. Granulocyte colony-stimulating factor 
Methods

Collection of CB
Collection of CB in the Obstetric Department of our university, was performed after informed consent of the mother. After delivery of the baby with the placenta still in utero, the umbilical cord was doubly clamped and transected 7-10 cm away from the umbilicus. After disinfection of the cord, the umbilical vein was punctured and CB collected into 150 ml collection bags (Macopharma, MS 2204Q, Langen, Germany) containing 21 ml citrate-phosphate dextrose (CPD) as anticoagulant.
Freezing and thawing of the CB
The unseparated CB sample was resuspended v/v in icecold freezing medium (70% RPMI-1640 without phenol red (ICN, Costa Mesa, CA, USA), 20% dimethylsulfoxide (Cryoserv, WAK-Chemie, Bad Soden, Germany) and 10% human serum albumin (Behring, Marburg, Germany) as described previously. 10 Four freezing bags were immediately placed in an automatic nitrogen freezer (Cryoson, Schöllkrippen, Germany) and cooled down to Ϫ100°C within a 70 min period. The frozen samples were placed into the liquid phase of nitrogen tanks (Messer Griesheim, Oberhausen, Germany).
Thawing of the CB bags was performed as described by Rubinstein et al. 11 One bag, containing 1/8 of the total cell count was thawed 10 days prior to transplantation, the three other bags (containing 7/8 of the transplant) at the time of transplantation.
Isolation of CD34
ϩ cells from the frozen CB sample 1/8 of the CB unit was thawed in a 37°C waterbath, washed twice in Dextran/HSA according to the protocol of Rubinstein et al 11 and CD34 ϩ cells were isolated with the clinical selection device CliniMACS (Miltenyi Biotec, Bergisch Gladbach, Germany). The CD34 ϩ selection was performed according to the manufacturer's recommended procedure. The yield of CD34 ϩ cells recovered after purification was calculated as the total number of CD34 ϩ cells in the enriched CD34
ϩ fraction x 100/the total number of CD34 ϩ cells in the unseparated CB.
Ex vivo expansion of CD34 ϩ enriched progenitor cells over 10 days prior to transplantation
For expansion over 10 days, the CD34 ϩ selected CB cells (1 ϫ 10 4 /ml) were cultured in a liquid culture system in Teflon bags (American Fluoroseal Corporation, Gaithersburg, MD, USA) in X-VIVO 10 medium (Biowhittaker, Walkersville, MD, USA), 10% heat inactivated CB plasma containing 100 ng/ml each of the recombinant human flt3-ligand (specific activity у1 ϫ 10 6 U/mg, Genzyme, Cambridge, MA, USA), thrombopoetin (specific activity Ͼ8 ϫ 10 5 U/mg, Genzyme) and G-CSF (Granocyte 34; Rhône-Poulenc Rorer, Cologne, Germany). The cytokines were added twice at days 4 and 7 and half of the medium was replaced once after 7 days. The liquid cultures were incubated at 37°C and 5% CO 2 in a fully humidified atmosphere. After the 10 day culture period, the cells were harvested, washed twice in PBS containing 0.1% HSA, counted for WBC, plated in a CFC as well as LTC-IC assay and analyzed for the expression of CD34, CD45, CD61, CD13, CD14, CD3, CD56, HLA-DR, CD1a and CD83 by flow cytometry. For infusion the cells were suspended in 0.9% NaCl containing 0.1% HSA.
For CFC assays, 1 ϫ 10 4 CD34 ϩ enriched cells and the expanded cells were plated and scored after 14 days. For LTC-IC assays 5 ϫ 10 3 CD34 ϩ cells prior to expansion or 1 ϫ 10 4 expanded cells were plated on a stromal layer and the LTC-IC assay performed as described.
Human progenitor colony-forming assay
Hematopoietic progenitor cell assays were performed in a ready-to-use granulocyte-erythroid-macrophage-megakaryocyte colony-forming unit (CFU-GEMM) semi-solid medium, containing 0.3% methylcellulose, 5 U/ml hu-IL-3, 30 U/ml hu-IL-6, 10 U/ml hu-G-CSF, 3 U/ml hu-Epo and 15 ng/ml hu-SCF, provided by StemBio Research (Villejuif, France). For CFC assays, 1 ϫ ) at day 10 were seeded in triplicate, each in three wells of a 24-well cell culture plate (Costar, Cambridge, MA, USA). Cultures were incubated at 37°C in humidified air with 5% CO 2 and scored on day 14 by inverted microscopic examination. Colonies of more than 50 cells were counted and classified as derived from granulocyte/macrophage (CFU-GM), early erythroid (BFU-E) or multipotent (CFU-GEMM) progenitor cells according to established criteria.
Phenotype analysis by cytofluorometry
Frozen and subsequently thawed unseparated CB cells and the enriched CD34 ϩ preparation were simultaneously stained with phycoerythrin (PE)-conjugated CD34 (HPCA-2; Becton Dickinson, San Jose, CA, USA) and fluoresceinisothiocyanate (FITC)-conjugated CD45 (HLe-1; Becton Dickinson) as described previously. 10 The cells were incubated with the antibodies for 20 min at room temperature, washed, lysed and fixed using the Immunoprep-EPICS leukocyte preparation system in a Coulter Q-Pep EPICS Immunology workstation (Coulter, Krefeld, Germany). Cell suspensions were then analyzed using an EPICS Elite flow cytometer (Coulter).
In order to determine the subsets of the expanded cells, cells were stained simultaneously with PE-conjugated 
Long-term culture-initiating cell assay
LTC-IC assays were performed according to a technique previously described by Sutherland et al. 12 Briefly, mononuclear cells from healthy volunteer bone marrow donors were seeded in 25 cm 2 tissue culture flasks (Greiner, Nürt-ingen, Germany) at 2 ϫ 10 6 /ml in RPMI-1640 supplemented with 12.5% fetal calf serum (FCS; Gibco/Life Technologies, Eggenstein, Germany), 12.5% horse serum (Sigma, St Louis, MO, USA) and 10 Ϫ6 m hydrocortisone sodium succinate (Sigma) 4 ). The cultures were incubated for 6 weeks and fed weekly by removing half of the medium without cells and adding an equal volume of fresh medium. After 6 weeks of culture, the adherent and non-adherent cells were harvested and evaluated in a density of 1 ϫ 10 5 cells/ml for CFU-GM, BFU-E and CFU-GEMM as described above.
Chimerism analysis
Fluorescence in situ hybridization for the X and Y chromosomes was used to ascertain engraftment of the allogeneic male cord blood cells. The X-chromosome-specific DNA probe employed here is an alphoid repetitive sequence of 2.0 kb. The human Y-specific DNA repeat was obtained from Amersham (Braunschweig, Germany) and consists of a 2.45 kb sequence identical to the pHY2.1 probe. The probes were labeled with biotin by nick translation. In situ hybridization was performed as described previously.
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Results
CD34 ϩ selection and ex vivo expansion of 1/8 of the total CB transplant
The proportion of the CB unit which was thawed for expansion had a primary nucleated cell count of 1.4 ϫ 10 (Figure 2 ), 0.2% CD3 ϩ , Ͻ0.2% CD56 ϩ , Ͻ0.2% CD1a and Ͻ0.2% CD83 ϩ cells. As a result of this successful ex vivo expansion the patient received at the time of transplantation 4.4 ϫ 10 7 NC/kg BW counted in the thawed unseparated CB component and 1 ϫ 10 7 white blood cells generated from the ex vivo expanded component (Table 2 ) with the majority consisting of granulocytic (60%), myelomonocytic cells (30%) and with 5.2% of megakaryocytic progenitor cells. 
Aplasia and hematopoietic engraftment
Aplasia developed at day 0. At day ϩ2 after transplantation the infant developed a focal pneumonia with septic shock, a maximum C-reactive protein of 28 mg/dl and capillary leakage syndrome, which required treatment with vasopressors from days ϩ4 to ϩ13, C1 esterase inhibitor concentrate from days ϩ6 to ϩ16, and broad-spectrum antibiotics (teicoplanin, cetrazidime, liposomal amphotericin B). As of day ϩ4 the patient received 280 g/m 2 G-CSF BSA. At day ϩ5 the child developed a transient erythrodermia, which could not be identified as an acute GVHD by biopsy. The C-reactive protein declined to 7.4 mg/dl on day 11.
Hematopoietic reconstitution was documented first by peripheral leukocyte counts on days ϩ8 and ϩ14 as 350 and 700/l, respectively, and by absolute neutrophil counts of 310 and 410/l, respectively. Chimerism analysis by fluorescence in situ hybridization at days ϩ8 and ϩ14 (Figure 3 ) revealed 97% and 98% donor cells. Hematopoietic reconstitution continued to develop smoothly with ANC reaching 800/l at day ϩ28 and 1500/l at day ϩ34.
The patient's T cell and NK cell reconstitution could be documented at day ϩ37 with 330 CD3 ϩ cells/l and 40 CD56 ϩ cells/l by flow cytometry. Periodic FISH analysis confirmed complete and stable hematopoietic and lymphopoietic donor engraftment. At day ϩ42, while the infant was subfebrile, CMV was documented by bronchoscopy and treatment was initiated with ganciclovir for a total of 25 days. During this episode the patient again required G-CSF at the dose of 280 g/m 2 BSA, which was tapered at day ϩ60 and finally stopped at day ϩ63. Moderate diarrhoea was present from days ϩ37 to ϩ50 with Pseudomonas aeruginosa isolated from stool cultures. Altogether, the patient received 24 units of platelets (the final at day ϩ74) and 10 transfusions of packed red blood cells (with the final unit given at day ϩ70) after transplantation. Reticulocytes were first detected at day ϩ29 (2%) and increased to 8% at day ϩ76. The time to reach an absolute platelet count of 20 000 (50 000)/l was 75 (103) days and seems to have been influenced by transplant complications in this ϩ cells/l. Twelve months after transplantation, the patients peripheral blood counts were as follows: white cells 9800/l, with a normal differential count; hemoglobin, 13.5 g/dl; and platelets, 211 000/l. Recent check up 1 year after cord blood transplantation revealed clinical remission with a full donor chimerism and normal physical and mental development of the child.
Discussion
In spite of over five million presently available unrelated bone marrow donors worldwide, about one-third of leukemia patients with relapse are still not finding an HLAmatched donor when needed. In addition, since the median search time for an unrelated donor still requires over 4 months and because of the frequent severity of acute and chronic GVHD observed after unrelated bone marrow transplantation, within the last years this has prompted the development of several larger cord blood banks as providers for alternative allogeneic hematopoietic stem cell grafts, which are completely pretested and available immediately. 13 Already early calculations suggested that there might be enough hematopoietic progenitor and stem cells in an average CB sample to reconstitute overweight patients, but the ability to engraft may require growth factor-mediated expansion.
14 During the last years, the tyrosine kinase receptor Flt3/Flk-2 ligand, flt3-L was cloned 15 and synergistic effects with thrombopoietin and other growth factors were described in the regulation of proliferation of both primitive multipotent and lineage committed hematopoietic progenitor cells. [16] [17] [18] [19] [20] Previous results of our group 19 and others have demonstrated that committed progenitors as well as the more immature CFU-GEMM and LTC-IC can be amplified from CD34 ϩ enriched CB samples in suspension cultures within 7-14 days without exhausting the proliferative potential and, thus, it appeared possible to improve the hematopoietic recovery after CB transplantation by simultaneous application of such ex vivo amplified cells from a part of the whole cord blood generated 10 days prior to transplant date.
Since only one frozen CB bag was available and therefore expansion could not be performed prior to transplantation, Shpall et al 21 expanded CD34 ϩ cells from thawed CB, representing 40% of the total CB collection, which were given 10 days after transplantation of the unmanipulated CB. With this procedure no unexpected side-effects were observed in four adult patients. In order to improve the engraftment in the case presented here, 1/8 of the frozen CB was expanded prior to transplantation.
Although the patient's clinical course was complicated by pneumonia and a septic condition requiring catecholamine treatment, early engraftment of white blood cells and neutrophils was achieved and was critical in overcoming the life-threatening infectious complications and was a prerequisite for early T cell reconstitution. However, although about 5% megakaryocytic progenitors were detected in the expanded cell fraction, the clinical platelet recovery was not accelerated, probably influenced by CMV reactivation and ganciclovir therapy thereby presenting an additional complication in this patient. Alternatively, only 1/8 of the whole cord blood unit may not be sufficient to accelerate platelet production in vivo. In the meantime, another patient with ALL (body weight 11 kg) transplanted in Denver, Colorado, received a CB transplant from the Düsseldorf CB bank frozen in two bags. Half of this CB was thawed at day Ϫ10 and expanded. The expanded product as well as the unmanipulated product were infused on day 0. 21 The rapid engraftment 21 observed in this patient from Denver (ANC 500/l at day 15) is consistent with the data described here. The disease-free survival of this patient is now over 5 months (reported by Dr Quinones to the Eurocord Transplant Registry, Paris, France).
Clearly, the first prerequisite for ex vivo expansion prior to transplantation is the primary availability of CB units frozen in several bags.
More recently, several clinical trials applying the AastromReplicell System as a technical alternative, now commercially available for ex vivo expansion, have shown a net expansion of CB-CFC and cells from unseparated CB as reported by Jaroscak et al 22 and Stiff et al. 23 Since in these clinical trials, just one single bag containing the whole CB unit was available, the expanded product could only be given at day ϩ12. As a result, the engraftment time was not accelerated as compared to historical controls. However, the event-free survival in the group receiving additional expanded cells at day ϩ12 appeared to be higher, although the follow-up data are preliminary at this stage. 22 The data presented here, however, demonstrate that ex vivo expansion of parts of the CB sample is technically and clinically feasible well ahead of the scheduled transplant date and may contribute to overcoming the limitations of lower CFC and NC doses present in non-expanded CB. Thus, these results are not merely that of a case report but provide a novel and generally applicable avenue for cell component therapy. Here, directed ex vivo expansion of one part is employed in combination with another part of nonexpanded stem and progenitor cells of the unmanipulated transplant source. The full potential of this approach employing simultaneously ex vivo expanded as well as nonexpanded CB components from one and the same unit now needs to be determined further within a phase I/II clinical protocol. Within that study, the employment of a marker gene introduced at the start of ex vivo expansion in order to follow the fate of these cells in the patient, would appear almost a necessity. A comparison among matched pairs of the relative efficiency of unexpanded CB units and of partially ex vivo expanded CB units given at day ϩ12 to the approach presented here will be performed within the EUROCORD/NETCORD organizations. For reasons of identical product quality the standard operational procedures of these EUROCORD/NETCORD 'cell factories', which may in the future offer their ex vivo expansion services upon specific request to the respective stem cell transplant centers, will have to be compatible and audited by the FAHCT-ISHAGE authorities.
If successful, the addition of selectively ex vivo expanded CB components with distinct cytokine cocktails may become a routine approach of cell therapy for several diseases as discussed recently by Parkman. 24 
